Cargando…
Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
By 2030, pancreatic cancer will become the second leading cause of cancer-related deaths in the United States and in Europe. The management of patients with advanced pancreatic cancer relies on chemotherapy and poly (ADP-ribose) polymerase inhibitors for patients who carry BRCA1/2 inactivating alter...
Autores principales: | Debbabi, Inès, Vacher, Sophie, Neuzillet, Cindy, Cros, Jérome, Revillon, Françoise, Petitalot, Ambre, Turpin, Anthony, Antonio, Samantha, Girard, Elodie, Dupain, Célia, Kamal, Maud, Hammel, Pascal, Bièche, Ivan, Masliah-Planchon, Julien, Caputo, Sandrine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869184/ https://www.ncbi.nlm.nih.gov/pubmed/36700131 http://dx.doi.org/10.1177/17588359221146132 |
Ejemplares similares
-
An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition
por: Muller, Danièle, et al.
Publicado: (2011) -
Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022) -
Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer
por: Caputo, Sandrine M., et al.
Publicado: (2018) -
Intrinsic Disorder and Phosphorylation in BRCA2 Facilitate Tight Regulation of Multiple Conserved Binding Events
por: Julien, Manon, et al.
Publicado: (2021) -
Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)